Biodexa shares surge 93.37% intraday as it launches eRapa global early/patient-specific access program with Tanner Pharma for FAP patients.

Biodexa surged 93.37% intraday, driven by the announcement that on April 1, Biodexa and Tanner Pharma launched the eRapa global early/patient-specific access program, providing FAP patients access to the investigational oral rapamycin capsule. Biodexa is a clinical-stage biopharmaceutical company focused on developing innovative therapies for gastrointestinal cancers, with eRapa as its core product candidate.